Janux Therapeutics (JANX) Stock Overview
A clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engager (TRACTr) and Tumor Activated Immunomodulator (TRACIr) platforms technology to treat patients with cancer. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
JANX Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Janux Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$25.11 |
| 52 Week High | US$71.71 |
| 52 Week Low | US$21.97 |
| Beta | 2.85 |
| 1 Month Change | -7.00% |
| 3 Month Change | 3.42% |
| 1 Year Change | -39.23% |
| 3 Year Change | 80.26% |
| 5 Year Change | n/a |
| Change since IPO | -0.16% |
Recent News & Updates
Janux: A High-Risk/High-Reward Bet On Oncology And Autoimmune Therapies Backed By $1B In Cash
Jul 31Here's Why We're Not At All Concerned With Janux Therapeutics' (NASDAQ:JANX) Cash Burn Situation
Apr 23
Recent updates
Janux: A High-Risk/High-Reward Bet On Oncology And Autoimmune Therapies Backed By $1B In Cash
Jul 31Here's Why We're Not At All Concerned With Janux Therapeutics' (NASDAQ:JANX) Cash Burn Situation
Apr 23Janux Therapeutics: Hype Breeds Volatility, And That Should Give You Pause
Dec 03Janux Therapeutics (NASDAQ:JANX) Is In A Strong Position To Grow Its Business
Oct 01Janux Therapeutics: Buoyed By Buyout Speculation
Sep 01Here's Why We're Not Too Worried About Janux Therapeutics' (NASDAQ:JANX) Cash Burn Situation
Jul 01Janux Therapeutics: A Prime Target In Cancer Care's M&A Game
Apr 11Janux: Additional Opportunity With JANX007 Dosing Update In The 2nd Half Of 2024
Feb 27Companies Like Janux Therapeutics (NASDAQ:JANX) Are In A Position To Invest In Growth
Feb 24Is Janux Therapeutics, Inc. (NASDAQ:JANX) Trading At A 37% Discount?
Dec 29Janux Therapeutics (NASDAQ:JANX) Is In A Good Position To Deliver On Growth Plans
Nov 04We're Hopeful That Janux Therapeutics (NASDAQ:JANX) Will Use Its Cash Wisely
Jul 20A Look At The Intrinsic Value Of Janux Therapeutics, Inc. (NASDAQ:JANX)
May 23Here's Why We're Not Too Worried About Janux Therapeutics' (NASDAQ:JANX) Cash Burn Situation
Feb 09We Think Janux Therapeutics (NASDAQ:JANX) Can Afford To Drive Business Growth
Oct 19Janux Therapeutics GAAP EPS of -$0.41, revenue of $2.37M
Aug 09We Think Janux Therapeutics (NASDAQ:JANX) Can Easily Afford To Drive Business Growth
Jun 05Janux Therapeutics (NASDAQ:JANX) Is In A Good Position To Deliver On Growth Plans
Feb 19Here's Why We're Not At All Concerned With Janux Therapeutics' (NASDAQ:JANX) Cash Burn Situation
Nov 03Shareholder Returns
| JANX | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 10.0% | 4.5% | 1.0% |
| 1Y | -39.2% | -5.1% | 17.1% |
Return vs Industry: JANX underperformed the US Biotechs industry which returned -6.5% over the past year.
Return vs Market: JANX underperformed the US Market which returned 17.4% over the past year.
Price Volatility
| JANX volatility | |
|---|---|
| JANX Average Weekly Movement | 6.8% |
| Biotechs Industry Average Movement | 10.8% |
| Market Average Movement | 6.4% |
| 10% most volatile stocks in US Market | 17.2% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: JANX has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: JANX's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2017 | 103 | David Campbell | www.januxrx.com |
Janux Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engager (TRACTr) and Tumor Activated Immunomodulator (TRACIr) platforms technology to treat patients with cancer. Its clinical candidates include JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor that is in Phase 1 clinical trial for the treatment of various solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, renal cell carcinoma, small cell lung cancer, pancreatic ductal adenocarcinoma, and triple-negative breast cancer. Janux Therapeutics, Inc. has strategic research collaboration agreement with Merck Sharp & Dohme Corp. to develop TRACTr product candidates.
Janux Therapeutics, Inc. Fundamentals Summary
| JANX fundamental statistics | |
|---|---|
| Market cap | US$1.50b |
| Earnings (TTM) | -US$105.64m |
| Revenue (TTM) | US$439.00k |
Is JANX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| JANX income statement (TTM) | |
|---|---|
| Revenue | US$439.00k |
| Cost of Revenue | US$68.39m |
| Gross Profit | -US$67.95m |
| Other Expenses | US$37.69m |
| Earnings | -US$105.64m |
Last Reported Earnings
Jun 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.76 |
| Gross Margin | -15,478.13% |
| Net Profit Margin | -24,064.01% |
| Debt/Equity Ratio | 0% |
How did JANX perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/08/15 05:29 |
| End of Day Share Price | 2025/08/15 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Janux Therapeutics, Inc. is covered by 16 analysts. 11 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Alec Stranahan | BofA Global Research |
| Justin Zelin | BTIG |
| Suranjit Mukherjee | BTIG |